196 related articles for article (PubMed ID: 30922252)
1. Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.
Halperin DM; Huynh L; Beaumont JL; Cai B; Bhak RH; Narkhede S; Totev T; Duh MS; Neary MP; Cella D
BMC Cancer; 2019 Mar; 19(1):274. PubMed ID: 30922252
[TBL] [Abstract][Full Text] [Related]
2. Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.
Halperin DM; Huynh L; Beaumont JL; Cai B; Totev T; Bhak RH; Duh MS; Neary MP; Cella D
Medicine (Baltimore); 2018 Nov; 97(47):e13390. PubMed ID: 30461659
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
4. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
5. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Joish VN; Frech F; Lapuerta P
J Med Econ; 2018 Feb; 21(2):182-188. PubMed ID: 28959913
[TBL] [Abstract][Full Text] [Related]
7. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.
Kiesewetter B; Duan H; Lamm W; Haug A; Riss P; Selberherr A; Scheuba C; Raderer M
Oncologist; 2019 Feb; 24(2):255-258. PubMed ID: 30171068
[TBL] [Abstract][Full Text] [Related]
8. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.
Pan IW; Halperin DM; Kim B; Yao JC; Shih YT
Pharmacoeconomics; 2021 Nov; 39(11):1271-1297. PubMed ID: 34378163
[TBL] [Abstract][Full Text] [Related]
10. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Pavel M; Gross DJ; Benavent M; Perros P; Srirajaskanthan R; Warner RRP; Kulke MH; Anthony LB; Kunz PL; Hörsch D; Weickert MO; Lapuerta P; Jiang W; Kassler-Taub K; Wason S; Fleming R; Fleming D; Garcia-Carbonero R
Endocr Relat Cancer; 2018 Mar; 25(3):309-322. PubMed ID: 29330194
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
Hörsch D; Anthony L; Gross DJ; Valle JW; Welin S; Benavent M; Caplin M; Pavel M; Bergsland E; Öberg K; Kassler-Taub KB; Binder P; Banks P; Lapuerta P; Kulke MH
Neuroendocrinology; 2022; 112(3):298-310. PubMed ID: 33940581
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
[TBL] [Abstract][Full Text] [Related]
13. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.
Broder MS; Cai B; Chang E; Yan T; Benson AB
J Med Econ; 2018 Aug; 21(8):821-826. PubMed ID: 29741466
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.
Burton T; Lapuerta P
Future Oncol; 2018 Oct; 14(23):2361-2370. PubMed ID: 30095284
[TBL] [Abstract][Full Text] [Related]
15. The impact of anemia on quality of life and healthcare resource utilization in patients with HIV/AIDS receiving antiretroviral therapy.
Bolge SC; Mody S; Ambegaonkar BM; McDonnell DD; Zilberberg MD
Curr Med Res Opin; 2007 Apr; 23(4):803-10. PubMed ID: 17407637
[TBL] [Abstract][Full Text] [Related]
16. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
17. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Cella D; Beaumont JL; Hudgens S; Marteau F; Feuilly M; Houchard A; Lapuerta P; Ramage J; Pavel M; Hörsch D; Kulke MH
Clin Ther; 2018 Dec; 40(12):2006-2020.e2. PubMed ID: 30477789
[TBL] [Abstract][Full Text] [Related]
18. Management of carcinoid syndrome: a systematic review and meta-analysis.
Hofland J; Herrera-Martínez AD; Zandee WT; de Herder WW
Endocr Relat Cancer; 2019 Mar; 26(3):R145-R156. PubMed ID: 30608900
[TBL] [Abstract][Full Text] [Related]
19. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
20. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.
Dillon JS; Chandrasekharan C
Future Oncol; 2018 May; 14(12):1155-1164. PubMed ID: 29350062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
